Guggenheim Maintains Buy on Damora Therapeutics, Lowers Price Target to $59
Should Trial Launch Require Action From Damora Therapeutics (DMRA) Investors?
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics Q3 EPS $(0.40) Beats $(0.48) Estimate
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
Damora Therapeutics’ Preclinical Data Highlighting Potential Of DMR-001 Accepted For Poster Presentation At 2026 ASH Annual Meeting And Exposition
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60
Damora Therapeutics: Potential Payday Is A Long Way Off
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.